Skip to main content

Opko Health Inc(OPK-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.1600
Day High1.2000
Open:1.1600
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Opko Health Inc

Select a category then submit the form to load news
Tipranks
H.C. Wainwright Reaffirms Their Buy Rating on Opko Health (OPK)
Tipranks
Opko Health Bets on Pipeline as Near-Term Profits Fade
Tipranks
Piper Sandler Sticks to Its Buy Rating for Opko Health (OPK)
GlobeNewswire
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
Motley Fool
OPKO Health (OPK) Q4 2025 Earnings Call Transcript
GlobeNewswire
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
Zacks Investment Research
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?
GlobeNewswire
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
GlobeNewswire
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Opko Health (OPK), Achieve Life Sciences (ACHV)
GlobeNewswire
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
Tipranks
Opko Health’s Strategic Moves Highlighted in Earnings Call
Tipranks
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), TransMedics Group (TMDX) and Opko Health (OPK)
Tipranks
OPKO Health Reports Q3 2025 Earnings and Strategic Moves
GlobeNewswire
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
GlobeNewswire
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
GlobeNewswire
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
Tipranks
Opko Health Sells BioReference Assets to Labcorp
Motley Fool
OPKO Health (OPK) Q2 2025 Earnings Call Transcript
Tipranks
OPKO Health’s Earnings Call: Strategic Moves Amid Challenges
Motley Fool
Opko Health (OPK) Q2 Revenue Falls 14%
GlobeNewswire
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
Tipranks
Opko Health (OPK) Has a New Rating from Ladenburg Thalmann & Co.
GlobeNewswire
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
GlobeNewswire
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
Tipranks
Piper Sandler Keeps Their Buy Rating on Opko Health (OPK)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
GlobeNewswire
OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Opko Health (OPK)
GlobeNewswire
OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025
GlobeNewswire
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Profile

OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.